Cell Medica Opens Commercial Manufacturing Facility - - BioPharm International

ADVERTISEMENT

Cell Medica Opens Commercial Manufacturing Facility


Cell Medica, a T cell therapeutics company, has opened a European manufacturing facility in Berlin-Buch, Germany to develop, manufacture, and market treatments of infections and cancers related to oncogenic viruses.

Cell Medica’s commercial manufacturing facility at the Max-Delbrück-Center of Molecular Medicine within the biotechnology area of Campus Berlin-Buch includes approximately 350 m2 cleanroom space, and will initially focus on manufacturing the company’s Cytovir CMV. The Cytovir CMV treatment uses immune cells of a healthy donor to restore immunity to Cytomegalovirus infections in patients who have lost their immunity following a bone marrow transplant. The commercial launch of Cytovir CMV is planned for early 2014, following the completion of two randomized controlled studies currently ongoing in the UK.
  
The facility will also be important in providing investigational medicine products for Cell Medica’s planned CITADEL study to investigate a T cell therapy for the treatment of EBV-associated lymphomas, which will be undertaken following the required regulatory approvals, the company reports.

Source: Cell Medica

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines

Click here